Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
about
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetesThe links between insulin resistance, diabetes, and cancerHyperglycemia as a risk factor for cancer progressionImpact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control studyLatest insights into the risk of cancer in diabetesExchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients.Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulinInvestigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse modelTreatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 PatientsComparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stuInsulin glargine use and breast cancer risk: Associations with cumulative exposureCancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.Metformin: are potential benefits on cancer risk extended to cancer survival?Pharmacologic treatment of type 2 diabetes: injectable medications.Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.Co-Managing Patients with Type 1 Diabetes and Cancer.New insights into antidiabetic drugs: Possible applications in cancer treatment.Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin.Self-controlled case series and misclassification bias induced by case selection from administrative hospital databases: application to febrile convulsions in pediatric vaccine pharmacoepidemiology.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer.Genome-Wide Analyses Identify Filamin-A As a Novel Downstream Target for Insulin and IGF1 Action.Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France.Report of the JDS/JCA Joint Committee on Diabetes and Cancer
P2860
Q26784381-158574D1-EC80-4918-AFF1-AE42BEF614B1Q26852910-939DBDEA-AA10-4E3F-8215-1598B513CA2CQ27687614-A448DD80-173A-4823-8F91-6A4629EE2873Q28535372-A45994F2-306A-4819-BDB1-CD0DFC97FBEDQ33588852-43C37EAD-535D-42B9-A7A2-32FA9620C70CQ33874996-BB485400-CC69-406E-8DE8-69ED8858860EQ34373861-2AC46442-A365-4490-9716-E31083EB4874Q34543063-798F8714-B865-46FF-B1A3-3BB7E23772BBQ35038355-994E6DF5-1E25-4147-B6C3-FD7A7F5A5A85Q35147769-0E9424FD-B8CA-4707-82DE-CC730E0B3F9EQ35937961-675FE743-13C5-4446-BEA6-88DB6FCBB3DBQ35974970-B2C4DA12-18EE-422E-8571-464F2034A232Q36027927-9F529744-2F30-45AB-BB5F-834F2A9B0176Q36947797-7C5BBC11-FF69-40C0-ADCB-DA12F3293362Q37154820-C5DA960C-F7B7-4B78-ABA9-8447FAEE99E7Q37278227-959BCC55-150C-4573-91B5-EF889C176FB1Q37404363-BF6395AE-9DD4-4459-9635-C726DFF22176Q38388602-AF36CE23-D727-42A5-A514-84E1FEF94FC4Q38426608-9E082ADB-AB7C-49F8-B47F-33D96E0D0215Q38749608-9E41C1C3-2435-4015-B1EC-C90CD9364A7FQ38764020-25351BCE-B758-4BC0-A2E0-EA449AF420B2Q38869694-B15FEC36-8719-4E75-929D-20C8F4645AC0Q39272833-916B5CAE-DD61-4945-8BAB-C83CB8373959Q41263604-DA0E7B89-A1EB-4DF6-A72D-7749C03A7BBAQ43848105-421F9B30-BF10-46E8-BAAC-517581FFA038Q46199321-2E61FFA4-55AA-4E00-840F-EB8CF3B288AEQ50488148-13B4B240-B6DF-4BCA-8D39-31D6ABFF1E34Q52608592-7245317F-12E0-4531-90E2-125DE04B8E43Q55513243-E618DAC1-CDB0-4614-8554-D54DFA8CA5B6Q57076958-AC7192E6-E278-487A-8807-16C202771CB6
P2860
Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Does insulin glargine increase ...... onal administrative databases.
@ast
Does insulin glargine increase ...... onal administrative databases.
@en
type
label
Does insulin glargine increase ...... onal administrative databases.
@ast
Does insulin glargine increase ...... onal administrative databases.
@en
prefLabel
Does insulin glargine increase ...... onal administrative databases.
@ast
Does insulin glargine increase ...... onal administrative databases.
@en
P2093
P2860
P356
P1433
P1476
Does insulin glargine increase ...... onal administrative databases.
@en
P2093
Alain Weill
Hubert Allemand
Jean-Paul Fagot
Philippe Ricordeau
Pierre-Olivier Blotière
P2860
P304
P356
10.2337/DC12-0506
P407
P577
2012-09-10T00:00:00Z